Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of DWP14012 Tablet A vs Tablet B in Healthy Subjects
NCT05149274Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Oct 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fexuprazan in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration and Maximum Plasma Concentration. Started Oct 2021; status: completed.
02
Drugs
fexuprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT05149274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05149274.